Australia To Continue AstraZeneca Vaccination Despite Blood Clotting Case

A 44-year-old man was admitted to a Melbourne hospital with clotting, days after receiving the AstraZeneca vaccine, suffering serious thrombosis, a condition that prevents normal blood flow though the circulatory system.

Australia will continue its inoculation programme with AstraZeneca PLC, health officials said on Saturday, after a blood clotting case raised concern about the safety of the vaccine. A 44-year-old man was admitted to a Melbourne hospital with clotting, days after receiving the AstraZeneca vaccine, suffering serious thrombosis, a condition that prevents normal blood flow though the circulatory system. The Therapeutic Goods Administration (TGA) regulator and a panel, the Australian Technical Advisory Group on Immunisation (ATAGI), met late Friday and early Saturday to discuss further advice on the AstraZeneca vaccine. "We have not been advised at this time by ATAGI or the TGA to pause the rollout of the AstraZeneca vaccine in Australia," Australia's deputy chief medical officer, Michael Kidd, told a televised briefing Saturday afternoon.